DSHEA at Thirty: The Supplement Framework That Built an Industry, and What It Did Not Anticipate

The Dietary Supplement Health and Education Act of 1994 — DSHEA — is the legislative framework that built the modern dietary supplement industry. Senators Hatch and Harkin steered it through Congress over the FDA's substantial objections. The structure it produced is unusual by international standards: dietary supplements are regulated under a food framework rather than a drug framework, with pre-market notification rather than pre-market approval, and with manufacturer responsibility for label-claim substantiation rather than regulatory verification of the same.

Thirty years on, DSHEA has done what its drafters wanted it to do. The category exists, it is large, it is broadly accessible, and the products available within it have proliferated. It has also done several things its drafters did not intend, including establishing a framework in which a meaningful share of supplements on the market do not contain what their labels claim, in the doses their labels claim, manufactured to the discipline their marketing implies. The published research on contamination, identity adulteration, and label-claim failure is at this point a mature field of its own.

What DSHEA accomplished

• Established dietary supplements as a regulated category distinct from foods and from drugs, with their own statutory definition and regulatory pathway.
• Created the structure-function claim framework that allows manufacturers to describe how a product affects the structure or function of the body without making disease-treatment claims.
• Codified manufacturer responsibility for label-claim substantiation, with FDA enforcement authority through post-market action.
• Preserved consumer access to products that had been available for decades without subjecting them to drug-grade pre-market approval requirements.
• Created the conditions under which the cGMP framework codified at 21 CFR Part 111 could subsequently be developed and enforced.

What DSHEA did not anticipate

DSHEA was drafted in 1994 to address vitamins, minerals, botanical extracts, amino acids, and dietary substances of those classes. It anticipated a market in which the principal regulatory question was access to safe, traditionally-used substances. It did not anticipate several developments that the supplement category has since absorbed.

• Peptide-class compounds, which sit awkwardly between dietary substances and pharmaceutical actives, with structure-function effects that the 1994 framework did not contemplate.
• The proliferation of proprietary blends that disclose ingredients without disclosing per-ingredient doses, a labelling practice that complicates substantiation in ways DSHEA did not address directly.
• The supplement-as-longevity-intervention category, in which products are marketed for explicit anti-aging effect against biomarkers that the DSHEA framework's structure-function language was not built to govern.
• The supplement industry's quality variance at scale — the documented fact that a meaningful share of products on shelves do not deliver what their labels claim, which the framework's post-market enforcement model has not been resourced to address comprehensively.
• Third-party verification programmes — USP, NSF, ConsumerLab, Informed Sport — that emerged to address quality variance and that DSHEA neither requires nor explicitly accommodates.

“DSHEA established the category. It did not, on its own, establish discipline within the category. A category-level standard is the layer that completes what DSHEA started.”

Where the Opticeutical Standard sits relative to DSHEA

The Opticeutical Standard does not displace DSHEA. It operates within DSHEA. Every product that bears the Opticeutical designation will continue to be regulated as a dietary supplement under the existing framework. Structure-function claims will continue to be substantiated under the existing requirements. cGMP manufacturing under 21 CFR Part 111 remains the baseline.

What the Standard adds is a category-level discipline that DSHEA does not require but does not prevent. Independent batch verification by accredited laboratories. Mechanism rationale tied to published research for every label claim. Sourcing integrity documented and traceable. Formulation discipline matched to the chemistry of the active compounds. The Standard is the layer that completes what DSHEA started.

On the relationship to peptide-class compounds specifically

The regulatory status of peptide-class compounds under DSHEA is one of the areas where the 1994 framework requires the most careful reading. Some peptide compounds qualify as dietary substances under the existing definitions; some do not; some require new dietary ingredient notifications; and some are appropriately routed through the compounding pharmacy framework rather than the dietary supplement framework. The Opticeutical category and the products that will bear its designation are organised entirely within the dietary supplement framework. The Atumnus Life Sciences IP portfolio includes compound architectures and delivery platforms designed to operate within DSHEA, not in tension with it.

DSHEA at thirty is, in our reading, a framework that did the work it was asked to do. The further discipline that the modern supplement category requires is not a DSHEA reform question. It is a category-standard question. The Opticeutical Standard is one answer to that question, applied to the specific category of optimized nutraceuticals with the rigour the underlying chemistry demands.